Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nutaria Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner within 1 distinct art unit. The portfolio's current activity is limited to this single pending matter. The use of 1 distinct art unit indicates a very focused prosecution path for the applicant.
The busiest examiner is ARNOLD, ERNST V, who is responsible for 1 busiest examiner pending action. This matches the total of 1 pending office action for the company. This means the entire current workload is concentrated under this one examiner. The 1 busiest examiner pending action managed by ARNOLD, ERNST V represents the entirety of the company's current workload.
Practitioners should focus on the 1 busiest examiner pending action by understanding the specific examination style of ARNOLD, ERNST V. This singular focus allows for a deep dive into the examiner's specific preferences to resolve the 1 pending office action. Understanding the specific requirements of the 1 distinct examiner is essential for success in the Biotechnology & Pharmaceuticals sector. This focused approach may lead to more consistent outcomes.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18601302 | TARGETED ENCAPSULATION STRATEGIES FOR TREATMENT MODALITIES | ARNOLD, ERNST V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18601302 | TARGETED ENCAPSULATION STRATEGIES FOR TREATMENT MODALITIES | ARNOLD, ERNST V | 1613 | §112 | Non-Final OA | — | Pending | Mar 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNutaria Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ernst V Arnold has the most, with 1 of Nutaria Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
